Literature DB >> 11413337

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.

M B Zwick1, L L Bonnycastle, A Menendez, M B Irving, C F Barbas, P W Parren, D R Burton, J K Scott.   

Abstract

Human monoclonal antibody (MAb) b12 recognizes a conformational epitope that overlaps the CD-4-binding site of the human immunodeficiency virus type 1 (HIV-1) envelope. MAb b12 neutralizes a broad range of HIV-1 primary isolates and protects against primary virus challenge in animal models. We report here the discovery and characterization of B2.1, a peptide that binds specifically to MAb b12. B2.1 was selected from a phage-displayed peptide library by using immunoglobulin G1 b12 as the selecting agent. The peptide is a homodimer whose activity depends on an intact disulfide bridge joining its polypeptide chains. Competition studies with gp120 indicate that B2.1 occupies the b12 antigen-binding site. The affinity of b12 for B2.1 depends on the form in which the peptide is presented; b12 binds best to the homodimer as a recombinant polypeptide fused to the phage coat. Originally, b12 was isolated from a phage-displayed Fab library constructed from the bone marrow of an HIV-1-infected donor. The B2.1 peptide is highly specific for b12 since it selected only phage bearing b12 Fab from this large and diverse antibody library.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413337      PMCID: PMC114393          DOI: 10.1128/JVI.75.14.6692-6699.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

2.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.

Authors:  X Liang; S Munshi; J Shendure; G Mark; M E Davies; D C Freed; D C Montefiori; J W Shiver
Journal:  Vaccine       Date:  1999-07-16       Impact factor: 3.641

4.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies?

Authors:  K Ariyoshi; E Harwood; R Chiengsong-Popov; J Weber
Journal:  Lancet       Date:  1992-11-21       Impact factor: 79.321

6.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries.

Authors:  C F Barbas; T A Collet; W Amberg; P Roben; J M Binley; D Hoekstra; D Cababa; T M Jones; R A Williamson; G R Pilkington
Journal:  J Mol Biol       Date:  1993-04-05       Impact factor: 5.469

9.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

Authors:  A J Conley; J A Kessler; L J Boots; J S Tung; B A Arnold; P M Keller; A R Shaw; E A Emini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

View more
  48 in total

1.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Mapping of Taenia solium TSOL18 antigenic epitopes by phage display library.

Authors:  Aijiang Guo; Xuepeng Cai; Wanzhong Jia; Bing Liu; Shaohua Zhang; Peiya Wang; Hongbing Yan; Xuenong Luo
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

3.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

4.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 5.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 6.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

7.  Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes.

Authors:  Melita B Irving; Lisa Craig; Alfredo Menendez; Beechanahalli P Gangadhar; Marinieve Montero; Nienke E van Houten; Jamie K Scott
Journal:  Mol Immunol       Date:  2009-12-23       Impact factor: 4.407

8.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

9.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

Authors:  Julia Gavrilyuk; Hitoshi Ban; Hisatoshi Uehara; Shannon J Sirk; Karen Saye-Francisco; Angelica Cuevas; Elise Zablowsky; Avinash Oza; Michael S Seaman; Dennis R Burton; Carlos F Barbas
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

10.  Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Authors:  Nienke E van Houten; Kevin A Henry; George P Smith; Jamie K Scott
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.